Neurolixis to Present Positive Proof-of-Concept Results on NLX-112 at World Parkinson’s Congress  (WPC).

NLX-112, a first-in-kind, highly selective, serotonin 5-HT1A receptor activator, recently underwent a successful Phase 2A clinical trial for treatment of levodopa-induced dyskinesia in Parkinson's disease. The detailed results from the trial, which met its primary and secondary endpoints, will be presented at the WPC in Barcelona as a poster on Wednesday July 5th 2023 (poster board # LBP38.31) and in an oral presentation on Friday July 7th 2023 (morning Hot Topics session). If you are attending this meeting, come and meet us!

See the full press release.